A selective ghrelin-receptor agonist studied for stimulating growth-hormone release with comparatively little effect on cortisol or prolactin, making it a frequently referenced 'clean' secretagogue.
Mechanism under study
Activates the ghrelin (GHS-R1a) receptor on the pituitary to trigger a growth-hormone pulse, and is often combined with a GHRH analog for a synergistic release.
Research-reported dosing
Research references commonly cite ~100–300 mcg per dose, one to three times daily, frequently paired with a GHRH analog. Not established in humans.
Based on a standard 5 mg vial: with 2 mL bacteriostatic water = 2,500 mcg/mL (2.5 mg/mL); 1 unit ≈ 25 mcg.
A 300 mcg dose ≈ 12 units (25 mcg per unit).
Open this mix in the calculator →Source research-grade Ipamorelin ↗Dosing figures describe how this compound appears in the research literature and research-community references. They are not a recommendation for human use.
Ipamorelin comparisons
Ipamorelin FAQ
What is Ipamorelin?
A selective ghrelin-receptor agonist studied for stimulating growth-hormone release with comparatively little effect on cortisol or prolactin, making it a frequently referenced 'clean' secretagogue.
What is the half-life of Ipamorelin?
Approximately 2 hours.
What is the research-reported dosing for Ipamorelin?
Research references commonly cite ~100–300 mcg per dose, one to three times daily, frequently paired with a GHRH analog. Not established in humans.
How is Ipamorelin reconstituted?
Based on a standard 5 mg vial: with 2 mL bacteriostatic water = 2,500 mcg/mL (2.5 mg/mL); 1 unit ≈ 25 mcg.
Is Ipamorelin FDA-approved?
No — Ipamorelin is not FDA-approved and is sold for laboratory research use only.
References
Guides featuring Ipamorelin
Related peptides
CJC-1295
Growth-hormone-releasing hormone (GHRH) analog
A synthetic GHRH analog studied for stimulating growth-hormone release. Exists in a short-acting 'no-DAC' form (modified GRF 1-29) and a long-acting 'DAC' form.
GHRP-2
Growth-hormone-releasing peptide (ghrelin-receptor agonist)
A potent growth-hormone-releasing peptide and ghrelin-receptor agonist studied for stimulating GH release; also investigated as a diagnostic test of pituitary GH reserve.
GHRP-6
Growth-hormone-releasing peptide (ghrelin-receptor agonist)
An early growth-hormone-releasing hexapeptide notable in research for a pronounced appetite-stimulating (hunger) effect alongside GH release.